Aristides Capital’s Omnicell OMCL Stock Holding History

Aristides Capital’s Portfolio OMCL Stock Details OMCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,153	Closed	-$269K	–	333
2023 Q4	$269K	Buy	+7,153	New	+$263K	0.1%	148
2023 Q1	–	Sell	-4,698	Closed	-$237K	–	223
2022 Q4	$237K	Buy	+4,698	New	+$282K	0.12%	135

Other funds holding OMCL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Aristides Capital's OMCL Position: Q1 2024 in Review

Aristides Capital sold out of Omnicell (OMCL) in Q1 2024, closing a stake of 7,153 shares — an estimated $269K sold.

Aristides Capital first reported a position in OMCL in Q4 2022 and held it in 2 quarters. The position peaked at $269K in Q4 2023. 266 funds tracked by Wall St. Rank hold OMCL as of Q1 2024.

Aristides Capital reported no remaining Omnicell position as of Q1 2024 after selling out during the quarter.
Aristides Capital sold 7,153 Omnicell shares in Q1 2024, an estimated $269K.
Aristides Capital first reported a position in Omnicell in Q4 2022 and held it in 2 quarters.
Aristides Capital's Omnicell position peaked at $269K in Q4 2023.
266 funds tracked by Wall St. Rank held Omnicell as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.